Acceleron Pharma Inc. (XLRN) - NASDAQ
  • Fri, Jun. 10, 7:50 AM
    • Acceleron Pharma (NASDAQ:XLRN) and development partner Celgene (NASDAQ:CELG) announce preliminary results from a Phase 2 clinical trial evaluating Fast Track-tagged luspatercept in patients with beta thalassemia, an inherited blood disorder that reduces the production of hemoglobin. The results were presented at the 21st Congress of the European Hematology Association in Copenhagen.
    • 80% (n=24/30) of patients treated with luspatercept achieved at least a 20% reduction in transfusion burden while 36% (n=8/22) achieved an increase in hemoglobin of at least 1.5 g/dL (normal range for men: 13.5 - 17.5 g/dL; women: 12.0 - 15.5 g/dL). In the long-term extension study the proportions improved to 96% (n=23/24) and 56% (n=15/27), respectively.
    • Luspatercept is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta superfamily, proteins that induce programmed cell death (apoptosis). A Phase 3 study in beta thalassemia, BELIEVE, is ongoing.
    • Acceleron will host a conference call this morning at 8:00 am ET to discuss the data.
    | Fri, Jun. 10, 7:50 AM | 4 Comments
  • Thu, May 5, 7:14 AM
    • Acceleron Pharma (NASDAQ:XLRN): Q1 EPS of $0.13 beats by $0.39.
    • Revenue of $18.2M (+311.8% Y/Y) beats by $8.71M.
    • Press Release
    | Thu, May 5, 7:14 AM | 1 Comment
  • Fri, Mar. 4, 9:44 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $75 (6% downside risk).
    • Acceleron Pharma (NASDAQ:XLRN) upgraded to Buy from Neutral by Janney Capital. Price target lowered to $39 (39% upside) from $45.
    • Keryx Biopharmaceuticals (NASDAQ:KERX) upgraded to Outperform from Market Perform by FBR Capital. Price target is $10 (145% upside).
    • Zimmer Biomet Holdings (NYSE:ZBH) downgraded to Hold from Buy by Argus Research.
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Hold from Buy by Canaccord Genuity. Price target lowered to $75 (15% upside) from $125. Downgraded to Sector Perform from Outperform by RBC Capital. Price target lowered to $85 (31% upside) from $194.
    • TeamHealth Holdings (NYSE:TMH) downgraded to Hold from Buy by Jefferies. Price target lowered to $65 (44% upside).
    • McKesson (NYSE:MCK) downgraded to Neutral from Buy by Mizuho Securities. Price target lowered to $164 (1% upside).
    • Diplomat Pharmacy (NYSE:DPLO) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $30 (9% upside) from $52.
    • Rockwell Medical (NASDAQ:RMTI) downgraded to Hold from Buy by Stifel. $19 price target removed. Also downgraded to Hold from Buy by Craig-Hallum.
    • China Biologic Products (NASDAQ:CBPO) downgraded to Neutral from Outperform by Credit Suisse. Price target raised to HK$129.
    • Orexigen Therapeutics (NASDAQ:OREX) downgraded to Sector Perform from Outperform by RBC Capital. Price target lowered to $1 (43% upside) from $5.
    • Vivus (NASDAQ:VVUS) downgraded to Sector Perform from Outperform by RBC Capital. Price target lowered to $1 (6% downside risk) from $4.
    | Fri, Mar. 4, 9:44 AM | 24 Comments
  • Thu, Feb. 25, 7:20 AM
    • Acceleron Pharma (NASDAQ:XLRN): Q4 EPS of -$0.81 misses by $0.72.
    • Revenue of $3.8M (+1.6% Y/Y) misses by $11.9M.
    • Press Release
    | Thu, Feb. 25, 7:20 AM
  • Fri, Jan. 22, 8:23 AM
    • Credit Suisse analysts have been very busy lately with a long list of initiations: Acceleron Pharma (NASDAQ:XLRN) Outperform with $50 (47% upside) price target; BioMarin Pharmaceutical (NASDAQ:BMRN) Outperform with $110 (36% upside) price target; Amgen (NASDAQ:AMGN) Outperform with $205 (34% upside) price target.
    • Celgene (NASDAQ:CELG) Outperform with $149 (41% upside) price target; Coherus Biosciences (NASDAQ:CHRS) Outperform with $25 (79% upside) price target; Gilead Sciences (NASDAQ:GILD) Outperform with $125 (40% upside) price target.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) Neutral with $552 (19% upside) price target; Vertex Pharmaceuticals (NASDAQ:VRTX) Outperform with $151 (59% upside) price target; Alnylam Pharmaceuticals (NASDAQ:ALNY) Outperform with $154 (117% upside) price target.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) Neutral rating with $201 (29% upside) price target; Biogen (NASDAQ:BIIB) Neutral with $322 (23% upside) price target; XenoPort (NASDAQ:XNPT) Underperform with $4 (16% downside risk) price target.
    • PTC Therapeutics (NASDAQ:PTCT) Outperform with $36 (33% upside) price target; Mesoblast Limited (NASDAQ:MESO) Outperform with $10 (92% upside) price target and Incyte (NASDAQ:INCY) Outperform with $110 (49% upside) price target.
    | Fri, Jan. 22, 8:23 AM | 3 Comments
  • Tue, Jan. 5, 7:43 PM
    • Acceleron Pharma (NASDAQ:XLRN) has priced its public offering of 3.75M shares of common stock, at $40/share.
    • Shares tumbled 10.3% today in the wake of last night's announcement of the offering, to close at $40.22.
    • As expected, gross proceeds will come to $150M; underwriters have a 30-day greenshoe option. Net proceeds are expected at about $140.4M, which will be put toward clinical trials and related activities.
    • Previously: Acceleron initiates $150M equity offering (Jan. 04 2016)
    | Tue, Jan. 5, 7:43 PM
  • Mon, Jan. 4, 5:11 PM
    • Acceleron Pharma (NASDAQ:XLRN) commences a $150M public offering of common stock. Volume, price and terms have yet to be announced.
    • Net proceeds will fund the clinical development of ADE-083 and other candidates, R&D, capex, working capital and general corporate purposes.
    | Mon, Jan. 4, 5:11 PM | 1 Comment
  • Dec. 7, 2015, 7:18 AM
    • Acceleron Pharma (NASDAQ:XLRN) announces that the FDA has designated luspatercept for Fast Track review for the treatment anemia in patients with lower-risk myelodysplastic syndromes.
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    • Luspatercept, being co-developed with Celgene (NASDAQ:CELG) is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta superfamily, proteins that induce programmed cell death (apoptosis).
    • The FDA designated luspatercept for Fast Track review for the treatment of beta thalassemia in May.
    • Previously: Luspatercept Fast Track'd for beta thalassemia (May 18)
    • Previously: Acceleron's luspatercept shows encouraging results in Phase 2 trials (June 15)
    | Dec. 7, 2015, 7:18 AM | 2 Comments
  • Nov. 4, 2015, 7:02 AM
    • Acceleron Pharma (NASDAQ:XLRN): Q3 EPS of -$0.36 beats by $0.10.
    • Revenue of $4.16M (+18.5% Y/Y) misses by $0.22M.
    | Nov. 4, 2015, 7:02 AM
  • Aug. 6, 2015, 7:20 AM
    • Acceleron Pharma (NASDAQ:XLRN): Q2 EPS of -$0.32 beats by $0.17.
    • Revenue of $5.72M (+40.2% Y/Y) beats by $1.49M.
    | Aug. 6, 2015, 7:20 AM
  • Jun. 15, 2015, 5:34 PM
    • Preliminary results from a Phase 2 clinical trial assessing Acceleron Pharma's (NASDAQ:XLRN) luspatercept in patients with lower risk myelodysplastic syndromes (MDS) show that three month's treatment with luspatercept increased hemoglobin levels and achieved transfusion independence in lower MDS patients. Longer term treatment produced sustained benefit for six months, possibly longer. The data were presented at the 20th Congress of the European Hematology Association in Vienna, Austria.
    • Results from the 12-month extension study show that low transfusion burden patients (n=9) experienced a mean hemoglobin increase of ~2 g/dL (normal range: 13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women) at one month which increased as high as 3.0 g/dL and was maintained for the six-month period for which data are available. In transfused patients, 43% achieved transfusion independence with several maintaining independence for more than six months.
    • Also on a preliminary basis, data from a Phase 2 trial in beta thalassemia showed that 38% of patients treated with luspatercept experienced a mean increase in hemoglobin of at least 1.5 g/dL for at least nine weeks. In non-transfusion dependent patients who had iron overload (n=12), eight (67%) experienced reduced liver iron concentrations of 1-4.6 mg/g dry weight over a 16-week period. In transfusion dependent patients, 100% (n=10/10) who received luspatercept had more than a 40% reduction in transfusion burden while two of three with iron overload showed reduced liver iron concentration by 1.96 and 4.7 mg/g dry weight, respectively (reference value = ~1.8 mg/g dry weight).
    • Luspatercept, being co-developed with Celgene (NASDAQ:CELG) is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta superfamily, proteins that induce programmed cell death (apoptosis).
    | Jun. 15, 2015, 5:34 PM | 9 Comments
  • Jun. 9, 2015, 9:05 AM
    • Acceleron Pharma (NASDAQ:XLRN) will host a conference call and live webcast on June 15 at 10:00 am ET to review the highlights of two oral presentations on the luspatercept Phase 2 clinical trials in myelodysplastic syndromes and beta thalassemia given at the 20th Congress of the European Hematology Association.
    • Fast Track-designated Luspatercept, being co-developed with Celgene (NASDAQ:CELG), is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta (TGF-beta) superfamily, proteins that induce programmed cell death or apoptosis.
    | Jun. 9, 2015, 9:05 AM | 4 Comments
  • May 18, 2015, 9:53 AM
    • The FDA designates luspatercept for Fast Track review for the treatment of patients with transfusion-dependent and non-transfusion-dependent beta thalassemia.
    • Beta thalassemia is genetic disorder caused by mutations in the HBB gene, which provides instructions for making beta-globulin, a protein subunit of hemoglobin. Sufferers are anemic and have increased risk of developing abnormal blood clots.
    • Luspatercept is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta (TGF-beta) superfamily, proteins that induce programmed cell death or apoptosis. It is being co-developed by Acceleron Pharma (XLRN +1.1%) and Celgene (CELG). A Phase 2 trial in beta-thalassemia is in process.
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    | May 18, 2015, 9:53 AM | 5 Comments
  • May 7, 2015, 7:09 AM
    • Acceleron Pharma (NASDAQ:XLRN): Q1 EPS of -$0.45 in-line.
    • Revenue of $4.42M (+33.5% Y/Y) beats by $0.19M.
    | May 7, 2015, 7:09 AM
  • May 5, 2015, 6:54 PM
    • An interim analysis of a Phase 2 trial evaluating luspatercept in patients with lower risk myelodysplastic syndromes (MDS) show that treatment with luspatercept increased hemoglobin levels and enabled many patients to become transfusion independent.
    • Data from 44 of 58 patients were available for analysis. In the higher dose groups (0.75 to 1.75 mg/kg subcutaneously every three weeks) 54% (n=24/44) showed increased hemoglobin. 36% of patients who received red blood cell transfusions during the eight weeks prior to treatment in the study achieved transfusion independence for at least eight weeks during the study.
    • In patients considered positive for ring sideroblasts (abnormal red blood cell precursor cells in the bone marrow), 63% showed increased hemoglobin and 39% achieved transfusion independence. RS-positive patients, representing ~30% of all MDS sufferers, are more resistant to treatment.
    • Luspatercept is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta (TGF-beta) superfamily, proteins that induce apoptosis (cell death). It is being co-developed by Acceleron Pharma (NASDAQ:XLRN) and Celgene (NASDAQ:CELG).
    • The data were presented at the 13th International Symposium on Myelodysplastic Syndromes in Washington, DC.
    • Previously: Celgene and Acceleron Pharma to start Phase 3 study to assess luspatercept in blood disorders (April 30)
    | May 5, 2015, 6:54 PM | 6 Comments
  • Apr. 30, 2015, 12:58 PM
    • Acceleron Pharma (XLRN -5.2%) and collaboration partner Celgene (CELG -3.7%) plan to initiate a Phase 3 study by year-end to evaluate Acceleron's luspatercept for the treatment of myelodysplastic syndromes (MDS) and beta thalassemia.
    • Luspatercept is a protein therapeutic called a ligand trap. It promotes red blood cell formation by inhibiting members of the transforming growth factor beta (TGF-beta) superfamily, proteins that induce apoptosis (cell death).
    • Preliminary data from an ongoing Phase 2 trial of luspatercept in MDS will be presented on May 2 at the 13th International Symposium on Myelodysplastic Syndromes in Washington, DC.
    • Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow fail to mature. The abnormally low level of circulating blood cells leads to anemia and its associated problems. Beta thalassemia is a blood disorder caused by mutations in the HBB gene that results in insufficient production of hemoglobin. These patients are also anemic.
    • The companies established their collaboration in 2008 to develop and commercialize sotatercept (ACE-011) for the treatment of anemia in rare blood diseases. They added luspatercept (ACE-536) in 2011. Sotatercept is also a TGF-beta-targeting protein therapeutic, but with a different mechanism of action.
    | Apr. 30, 2015, 12:58 PM | 2 Comments
Company Description
Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States